Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fragile X Syndrome - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Fragile X Syndrome - Overview 6 Fragile X Syndrome - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Fragile X Syndrome - Therapeutics Assessment 14 Assessment by Target 14 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Fragile X Syndrome - Companies Involved in Therapeutics Development 22 Aelis Farma SAS 22 AMO Pharma Ltd 22 Anavex Life Sciences Corp 23 Confluence Pharmaceuticals LLC 23 DRI Biosciences Corp 24 Eli Lilly and Company 24 Fulcrum Therapeutics Inc 25 GlaxoSmithKline Plc 25 GW Pharmaceuticals Plc 26 Marinus Pharmaceuticals Inc 26 Neuren Pharmaceuticals Ltd 27 Neuron Biopharma SA 27 Ovid Therapeutics Inc 28 Sage Therapeutics Inc 28 Zynerba Pharmaceuticals Inc 29 Fragile X Syndrome - Drug Profiles 30 acamprosate calcium - Drug Profile 30 ACT-01 - Drug Profile 31 AMO-01 - Drug Profile 32 ANAVEX-273 - Drug Profile 34 Bryostatin-1 - Drug Profile 44 cannabidiol - Drug Profile 49 cercosporamide - Drug Profile 54 Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 56 flindokalner - Drug Profile 57 gaboxadol - Drug Profile 58 ganaxolone - Drug Profile 60 JRP-655 - Drug Profile 67 NNZ-2591 - Drug Profile 68 NST-0076 - Drug Profile 70 SAGE-217 - Drug Profile 71 SGE-872 - Drug Profile 74 Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile 75 Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile 76 Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile 77 Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile 78 Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile 79 Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile 80 Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 81 SRT-278 - Drug Profile 82 TC-2153 - Drug Profile 83 trofinetide - Drug Profile 84 Fragile X Syndrome - Dormant Projects 92 Fragile X Syndrome - Discontinued Products 94 Fragile X Syndrome - Product Development Milestones 95 Featured News & Press Releases 95 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 105 Disclaimer 106
List of Tables
Number of Products under Development for Fragile X Syndrome, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Fragile X Syndrome - Pipeline by Aelis Farma SAS, H1 2017 Fragile X Syndrome - Pipeline by AMO Pharma Ltd, H1 2017 Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2017 Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H1 2017 Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H1 2017 Fragile X Syndrome - Pipeline by Eli Lilly and Company, H1 2017 Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H1 2017 Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017 Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2017 Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H1 2017 Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017 Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H1 2017 Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H1 2017 Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H1 2017 Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017 Fragile X Syndrome - Dormant Projects, H1 2017 Fragile X Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017 Fragile X Syndrome - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.